Price
No data yet.
Social Signal Score
Analyst Ratings
Revenue
$13.94MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sudhir Prem Srivastava
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 483
- Beta
- 0.67
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 7.40
Financials
Revenue
$13.94M+3666.3%Net Income
$-2.66MEBITDA
$-1.92MFree Cash Flow
$-4.40MEPS (diluted)
$-0.01Shares Outstanding (diluted)
209.42M+9938.1%Operating Expenses
$6.85MCash & Debt
$13.65MReturn of Capital
$0.00Revenue by Segment (annual)
$38.35MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $42.48M | $-12.13M | $-0.06 |
| 2024 | $20.65M | $-19.15M | $-0.11 |
| 2023 | $5.88M | $-20.94M | $-0.16 |
| 2022 | $1.46M | $-5.60M | $-1.41 |
| 2021 | $0.00 | $-1.48M | $-0.52 |
| 2020 | $0.00 | $-1.12M | $-0.48 |
| 2019 | $0.00 | $-3.39M | $-1.57 |
| 2018 | $0.00 | $-960.3K | $-0.46 |
| 2017 | $0.00 | $-1.04M | $-0.53 |
| 2016 | $0.00 | $-485.0K | $-0.25 |
| 2015 | $0.00 | $-66.00 | $0.00 |
Valuation
SSIIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
75-37.50%Social Signal Score
Mentions (3)
- Newszacks.com·6h ago·Negative
Zacks Initiates Coverage of SSi With Neutral Recommendation Discover why Zacks initiated coverage of SSII with a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Explore how expanding robotic surgery adoption, rising revenues and international growth are offset by persistent losses and regulatory hurdles.
View source ↗ - Newsglobenewswire.com·29d ago·Neutral
…d utilization -- FORT LAUDERDALE, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- via IBN -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today provided an update on the Company's continuing progress and milestones.
View source ↗ - Newsglobenewswire.com·57d ago·Positive
SS Innovations Reports Second Quarter 2026 Financial Results Record quarterly revenue driven by continuing strong growth in SSi Mantra unit sales Record quarterly revenue driven by continuing strong growth in SSi Mantra unit sales
View source ↗
Earnings
Tue, Nov 3(in 3 weeks)
Consensus estimate $-0.01 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.01 vs $-0.01beat
- Wed, May 13$-0.02 vs $-0.02beat
Estimates and results for SSII via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SSII officers and directors.
- Bought
- $17.0m
- Sold
- $16.1m
40 trades
8 trades
- Sudhir Srivastavasold
- Moll Frederic Hbought
- Adams Timothy P.bought
- Sudhir Srivastavabought
- Cohen Barry Fbought
- Cohen Barry Fbought
- Cohen Barry Fbought
- Cohen Barry Fbought
52 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SSII.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.